

Active substances set

Search phrase: lenvatinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer

Lenvatinib

Lenvatinib as monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

 **NO REIMBURSEMENT**

 **ESMO**

Kidney cancer

Lenvatinib

Lenvatinib is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): - in combination with pembrolizumab, as first-line treatment, - in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)- targeted therapy.

 **NO REIMBURSEMENT**

 **ESMO**